The analysis of the study was based on intention to treat. The health measures consisted of:
number of cases of cardiotoxicity (including cases of abnormal electrocardiogram (ECG) changes),
number of cases of congestive heart failure (CHF),
number of cases of abnormal left ventricular ejection fraction (LVEF),
the rate of anthracycline-induced hospitalisation,
the median length of anthracycline-induced hospitalisation,
number of cases of myelosuppression (including cases of therapy delay and the percentage of therapeutic delay which occurred below the 400 mg/m-square cumulative dosage, cases of dose reduction and the percentage of dose reduction occurring below the 400 mg/m-square cumulative dosage),
the rate of FN-induced hospitalisation and the the median length of hospitalisation in thosecases,
the number of cases of septic death,
the overall trend of FN incidence.
The groups were shown to be comparable with respect to physical characteristics, diagnoses and metastatic sites.